TrialCompass™ TCL
Back to trials
Phase 1RecruitingPriority 4 · Lower priorityNCT07465835

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

ClinicalTrials.gov

Plain-language summary

This trial is testing ELA026 (an investigational agent given by weekly subcutaneous injection) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

ELA026 (DRUG): Weekly maintenance dosing via subcutaneous injection

  • ELA026

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

NCT07465835

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing ELA026 (an investigational agent given by weekly subcutaneous injection) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 6 locations in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

What's being tested

ELA026 (DRUG): Weekly maintenance dosing via subcutaneous injection

Drugs / treatments: ELA026

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 84 patients

Primary endpoint: DLTs and treatment emergent adverse events (TEAEs), including serious adverse advents (SAEs)

Ages: 18 Years to —

Start date: 2026-02-17 | Est. completion: 2028-12

Locations

6 US sites · 6 total

Connecticut, Georgia, Michigan, New York, Ohio, Texas

Contact

Clinical Trials Electra Clinical Trials Information | clinicaltrials@electra-therapeutics.com | Please email

Sponsor: Electra Therapeutics Inc. (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07465835

Prepared using TrialCompass (trialcompass.com) on August 18, 2026. For informational purposes only. Always discuss with your healthcare team.